Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrathiomolybdate + IFL in Metastatic Colorectal Cancer
NCT00176774Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Feb 2001
- Primary completion
- Feb 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tetrathiomolybdate in colorectal carcinoma (CRC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Tolerability and Toxicity at 12 months. Started Feb 2001; status: completed.
02
Drugs
tetrathiomolybdate
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00176774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176774.